InMed Pharmaceuticals

Yahoo Finance • 19 days ago

InMed Pharmaceuticals GAAP EPS of -$8.36, revenue of $4.94M

* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20241081-inmed-pharmaceuticals-reports-full-year-fiscal-2025-financial-results-and-provides-business] (NASDAQ:INM [https://seekingalpha.com/symbol/INM]): FY GAAP EPS of -... Full story

Yahoo Finance • 24 days ago

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now a... Full story

Yahoo Finance • 4 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story

Yahoo Finance • 4 months ago

InMed Pharmaceuticals announces $5M private placement

* InMed Pharmaceuticals (NASDAQ:INM [https://seekingalpha.com/symbol/INM]) has entered into definitive agreements for the issuance and sale of 1.95M of its common shares and short-term preferred investment options to purchase up to an ag... Full story

Yahoo Finance • 4 months ago

InMed's Alzheimer's drug candidate shows reduced inflammation in lab tests

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ:INM), a micro-cap pharmaceutical company with a market capitalization of approximately $3 million, announced Tuesday that its drug candidate INM-901 significantly reduced inflammation markers... Full story

Yahoo Finance • 4 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story

Yahoo Finance • 3 years ago

Presenting on the Emerging Growth Conference on March 8 Register Now

MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companie... Full story

Yahoo Finance • 3 years ago

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzh... Full story

Yahoo Finance • 3 years ago

InMed Provides Business Update and Milestones for 2023

Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as... Full story

Yahoo Finance • 3 years ago

InMed Announces Results of 2022 Annual General Meeting

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 3 years ago

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 3 years ago

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 3 years ago

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding

Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’sIdentified two lead cannabinoid analog compounds for in vivo studiesNSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar f... Full story

Yahoo Finance • 3 years ago

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 3 years ago

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to... Full story

Yahoo Finance • 3 years ago

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story

Yahoo Finance • 3 years ago

InMed Announces Changes to its Board of Directors

VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleas... Full story

Yahoo Finance • 3 years ago

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use... Full story

Yahoo Finance • 3 years ago

InMed Announces Appointment of Chief Operating Officer

VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story

Yahoo Finance • 3 years ago

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story